156 related articles for article (PubMed ID: 37302395)
41. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial.
Poortmans PM; Collette L; Horiot JC; Van den Bogaert WF; Fourquet A; Kuten A; Noordijk EM; Hoogenraad W; Mirimanoff RO; Pierart M; Van Limbergen E; Bartelink H;
Radiother Oncol; 2009 Jan; 90(1):80-5. PubMed ID: 18707785
[TBL] [Abstract][Full Text] [Related]
42. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial.
Poortmans PM; Collette L; Bartelink H; Struikmans H; Van den Bogaert WF; Fourquet A; Jager JJ; Hoogenraad W; Müller RP; Dubois JB; Bolla M; Van Der Hulst M; Wárlám-Rodenhuis CC; Pierart M; Horiot JC;
Cancer Radiother; 2008 Nov; 12(6-7):565-70. PubMed ID: 18760649
[TBL] [Abstract][Full Text] [Related]
43. Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study.
Reitsamer R; Peintinger F; Kopp M; Menzel C; Kogelnik HD; Sedlmayer F
Strahlenther Onkol; 2004 Jan; 180(1):38-44. PubMed ID: 14704843
[TBL] [Abstract][Full Text] [Related]
44. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
45. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial.
Livi L; Meattini I; Marrazzo L; Simontacchi G; Pallotta S; Saieva C; Paiar F; Scotti V; De Luca Cardillo C; Bastiani P; Orzalesi L; Casella D; Sanchez L; Nori J; Fambrini M; Bianchi S
Eur J Cancer; 2015 Mar; 51(4):451-463. PubMed ID: 25605582
[TBL] [Abstract][Full Text] [Related]
46. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
Saji H; Okada M; Tsuboi M; Nakajima R; Suzuki K; Aokage K; Aoki T; Okami J; Yoshino I; Ito H; Okumura N; Yamaguchi M; Ikeda N; Wakabayashi M; Nakamura K; Fukuda H; Nakamura S; Mitsudomi T; Watanabe SI; Asamura H;
Lancet; 2022 Apr; 399(10335):1607-1617. PubMed ID: 35461558
[TBL] [Abstract][Full Text] [Related]
47. The Salzburg concept of intraoperative radiotherapy for breast cancer: results and considerations.
Reitsamer R; Sedlmayer F; Kopp M; Kametriser G; Menzel C; Deutschmann H; Nairz O; Hitzl W; Peintinger F
Int J Cancer; 2006 Jun; 118(11):2882-7. PubMed ID: 16381011
[TBL] [Abstract][Full Text] [Related]
48. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Donker M; van Tienhoven G; Straver ME; Meijnen P; van de Velde CJ; Mansel RE; Cataliotti L; Westenberg AH; Klinkenbijl JH; Orzalesi L; Bouma WH; van der Mijle HC; Nieuwenhuijzen GA; Veltkamp SC; Slaets L; Duez NJ; de Graaf PW; van Dalen T; Marinelli A; Rijna H; Snoj M; Bundred NJ; Merkus JW; Belkacemi Y; Petignat P; Schinagl DA; Coens C; Messina CG; Bogaerts J; Rutgers EJ
Lancet Oncol; 2014 Nov; 15(12):1303-10. PubMed ID: 25439688
[TBL] [Abstract][Full Text] [Related]
49. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
50. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
Erlandsson J; Holm T; Pettersson D; Berglund Å; Cedermark B; Radu C; Johansson H; Machado M; Hjern F; Hallböök O; Syk I; Glimelius B; Martling A
Lancet Oncol; 2017 Mar; 18(3):336-346. PubMed ID: 28190762
[TBL] [Abstract][Full Text] [Related]
51. Weekly concomitant boost in adjuvant radiotherapy for patients with early breast cancer: preliminary results on feasibility.
Corvò R; Giudici S; Maggio F; Bevegni M; Sampietro C; Lucido MR; Orsatti M
Tumori; 2008; 94(5):706-11. PubMed ID: 19112945
[TBL] [Abstract][Full Text] [Related]
52. Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China.
Wang SL; Fang H; Hu C; Song YW; Wang WH; Jin J; Liu YP; Ren H; Liu J; Li GF; Du XH; Tang Y; Jing H; Ma YC; Huang Z; Chen B; Tang Y; Li N; Lu NN; Qi SN; Yang Y; Sun GY; Liu XF; Li YX
J Clin Oncol; 2020 Nov; 38(31):3604-3614. PubMed ID: 32780661
[TBL] [Abstract][Full Text] [Related]
53. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.
Strnad V; Ott OJ; Hildebrandt G; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Gutierrez Miguelez C; Slampa P; Allgäuer M; Lössl K; Polat B; Kovács G; Fischedick AR; Wendt TG; Fietkau R; Hindemith M; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Pötter R; Gall C; Malzer M; Uter W; Polgár C;
Lancet; 2016 Jan; 387(10015):229-38. PubMed ID: 26494415
[TBL] [Abstract][Full Text] [Related]
54. The effect of escalating the boost dose for patients with involved resection margin after breast-conserving surgery.
Park S; Ahn SD; Choi EK; Kim SS
Jpn J Clin Oncol; 2018 Mar; 48(3):272-277. PubMed ID: 29385496
[TBL] [Abstract][Full Text] [Related]
55. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
56. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
57. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial.
Schäfer R; Strnad V; Polgár C; Uter W; Hildebrandt G; Ott OJ; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Miguelez CG; Slampa P; Allgäuer M; Lössl K; Kovács G; Fischedick AR; Fietkau R; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Gall C; Polat B;
Lancet Oncol; 2018 Jun; 19(6):834-844. PubMed ID: 29695348
[TBL] [Abstract][Full Text] [Related]
58. Role of boost radiotherapy for local control of pure ductal carcinoma in situ after breast-conserving surgery: a multicenter, retrospective study of 622 patients.
Cambra MJ; Moreno F; Sanz X; Anglada L; Mollà M; Reyes V; Arenas M; Pedro A; Ballester R; García V; Casals J; Cusidó M; Jimenez C; Escribà JM; Macià M; Solé JM; Arcusa A; Seguí MA; Gonzalez S; Farrús B; Biete A
Clin Transl Oncol; 2020 May; 22(5):670-680. PubMed ID: 31264148
[TBL] [Abstract][Full Text] [Related]
59. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation.
Ono Y; Yoshimura M; Hirata K; Yamauchi C; Toi M; Suzuki E; Takada M; Hiraoka M; Mizowaki T
Radiat Oncol; 2019 Jul; 14(1):121. PubMed ID: 31291997
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
